摘要退缩人综合征（shrinking men syndrome,SMS）是维持性血液透析尿毒症患者很少见的严重慢性并发症,国内报道较少,其主要特征是以身高明显缩短伴骨痛、骨畸形、病理性骨折和皮肤瘙痒等症状的一组临床综合征[1]。目前认为肾性骨病和继发性甲状旁腺功能亢进是引起退缩人综合征的主要病因，现将内蒙古医学院第四附属医院维持性血液透析患者并发退缩人综合征2例报道如下：
5Fan S, Ross C, Mitra S, et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis[J]. Nephrol Dial Transplant, 2009, 24 (12): 3794-3799.
6Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis [J]. Clin J Am Soc Nephrol, 2008, 3 (4) : 1125-1130.
7Hutchison A J, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6 month, randomized, comparative trial versus calcium carbonate [J]. Nephron Clin Pract, 2005, 100(1) : 8-19.
8Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment [J]. Nephron Clin Pract, 2008, 110(1) : 15-23.
9Hayashi M, Tsuchiya Y, Itaya Y, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial[J]. Nephrol Dial Transplant, 2004, 19 (8): 2067-2073.
10Sprague M, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism[J]. Kidney Int, 2003, 63 (4): 1483-1490.
